Press Releases

MGEN $9.87   $0.42 | 4.44%

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
8/11/2017
4:05 PM ET
Earnings Release

miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

8/11/2017

New MRG-106 Phase 1 cutaneous T-cell lymphoma clinical trial data releasedExpansion of the MRG-106 trial to include additional potential indicationsTwo new independent members added to its Board of Di...

 Continue Reading
8/8/2017
7:00 AM ET
Press Release

miRagen Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

8/8/2017

BOULDER, Colo., Aug. 08, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
8/1/2017
7:00 AM ET
Press Release

miRagen Therapeutics to Announce Second Quarter 2017 Financial Results and Host Webcast Conference Call on August 11, 2017

8/1/2017

BOULDER, Colo., Aug. 01, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) will report its second quarter 2017 financial results on Friday, August 11, 2017, after the close of the U....

 Continue Reading
7/21/2017
10:00 AM ET
Press Release

miRagen Therapeutics, Inc. (Nasdaq: MGEN) to Ring The Nasdaq Stock Market Closing Bell

7/21/2017

ADVISORY, July 21, 2017 (GLOBE NEWSWIRE) --

What: miRagen Therapeutics, Inc. (Nasdaq:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-tar...

 Continue Reading
6/8/2017
7:00 AM ET
Press Release

miRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma

6/8/2017

BOULDER, Colo., June 08, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
Displaying 1 to 5 (of 21 releases)